GlassScriptPhysician profile
Patrick L Murphy
NPI 1316384936
$13,208.29
in general payments reported to CMS, 2019-2025
47 companies · $2,771 in 2025
The $2,771 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2020: $528 · 2021: $1,620 · 2022: $2,050 · 2023: $2,397 · 2024: $2,836 · 2025: $2,771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,004.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,004.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,522.74 | 2021-2025 | |
| Novo Nordisk INC | $1,398.09 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,235.30 | 2019-2025 | Evenity, Prolia, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,090.78 | 2019-2025 | Trulance, Xifaxan, Relistor |
| Janssen Pharmaceuticals, INC | $965.52 | 2019-2025 | Spravato, Xarelto |
| Astrazeneca Pharmaceuticals LP | $723.76 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $688.15 | 2021-2025 | |
| Lilly USA, LLC | $610.75 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $543.52 | 2019-2025 | |
| Astellas Pharma US INC | $363.65 | 2019-2025 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $333.49 | 2022-2025 | |
| Glaxosmithkline, LLC. | $327.70 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $253.54 | 2024-2025 | Gemtesa |
| Daiichi Sankyo INC. | $160.12 | 2019-2022 | |
| Shield Therapeutics INC | $147.44 | 2023-2025 | Accrufer |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.